BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 29728401)

  • 1. Immune regulatory cell infusion for graft-versus-host disease prevention and therapy.
    Blazar BR; MacDonald KPA; Hill GR
    Blood; 2018 Jun; 131(24):2651-2660. PubMed ID: 29728401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of Graft-Versus-Host Disease Control Efficacy by Adoptive Transfer of Type 1 Regulatory T Cells in Bone Marrow Transplant Model.
    Jeon YW; Lim JY; Im KI; Kim N; Nam YS; Song YJ; Cho SG
    Stem Cells Dev; 2019 Jan; 28(2):129-140. PubMed ID: 30381994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model.
    Lim JY; Park MJ; Im KI; Kim N; Jeon EJ; Kim EJ; Cho ML; Cho SG
    Cell Transplant; 2014 Apr; 23(6):703-14. PubMed ID: 23452894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory T cells in stem cell transplantation: strategies and first clinical experiences.
    Edinger M; Hoffmann P
    Curr Opin Immunol; 2011 Oct; 23(5):679-84. PubMed ID: 21802270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.
    Pierini A; Colonna L; Alvarez M; Schneidawind D; Nishikii H; Baker J; Pan Y; Florek M; Kim BS; Negrin RS
    J Immunol; 2015 Jul; 195(1):347-55. PubMed ID: 25994967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third-party regulatory T cells prevent murine acute graft-versus-host disease.
    Lim JY; Im KI; Song Y; Kim N; Nam YS; Jeon YW; Cho SG
    Korean J Intern Med; 2018 Sep; 33(5):980-989. PubMed ID: 29050459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can we prevent or treat graft-versus-host disease with cellular-therapy?
    Zahid MF; Lazarus HM; Ringdén O; Barrett JA; Gale RP; Hashmi SK
    Blood Rev; 2020 Sep; 43():100669. PubMed ID: 32089398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant.
    Garcia-Rosa M; Abraham A; Bertaina A; Bhoopalan SV; Bonfim C; Cohen S; DeZern A; Louis C; Oved J; Pavel-Dinu M; Purtill D; Ruggeri A; Russell A; Sharma A; Wynn R; Boelens JJ; Prockop S
    Cytotherapy; 2023 Jun; 25(6):578-589. PubMed ID: 36941149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease.
    Theil A; Tuve S; Oelschlägel U; Maiwald A; Döhler D; Oßmann D; Zenkel A; Wilhelm C; Middeke JM; Shayegi N; Trautmann-Grill K; von Bonin M; Platzbecker U; Ehninger G; Bonifacio E; Bornhäuser M
    Cytotherapy; 2015 Apr; 17(4):473-86. PubMed ID: 25573333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD.
    Haase D; Starke M; Puan KJ; Lai TS; Rotzschke O
    Immunol Res; 2012 Sep; 53(1-3):200-12. PubMed ID: 22418725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic use of regulatory T cells for graft-versus-host disease.
    Elias S; Rudensky AY
    Br J Haematol; 2019 Oct; 187(1):25-38. PubMed ID: 31418827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of induced and natural FoxP3(+) regulatory T cells for the treatment of Graft-versus-host disease.
    Prinz I; Koenecke C
    Arch Immunol Ther Exp (Warsz); 2012 Jun; 60(3):183-90. PubMed ID: 22476537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
    Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
    Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease.
    Parmar S; Liu X; Tung SS; Robinson SN; Rodriguez G; Cooper LJ; Yang H; Shah N; Yang H; Konopleva M; Molldrem JJ; Garcia-Manero G; Najjar A; Yvon E; McNiece I; Rezvani K; Savoldo B; Bollard CM; Shpall EJ
    Cytotherapy; 2014 Jan; 16(1):90-100. PubMed ID: 24480547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A glucocorticoid amplifies IL-2-induced selective expansion of CD4(+)CD25(+)FOXP3(+) regulatory T cells in vivo and suppresses graft-versus-host disease after allogeneic lymphocyte transplantation.
    Xie Y; Wu M; Song R; Ma J; Shi Y; Qin W; Jin Y
    Acta Biochim Biophys Sin (Shanghai); 2009 Sep; 41(9):781-91. PubMed ID: 19727527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease.
    Li M; Sun K; Welniak LA; Murphy WJ
    Expert Opin Pharmacother; 2008 Sep; 9(13):2305-16. PubMed ID: 18710355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-10 Gene-Modified Dendritic Cell-Induced Type 1 Regulatory T Cells Induce Transplant-Tolerance and Impede Graft Versus Host Disease After Allogeneic Stem Cell Transplantation.
    Wan J; Huang F; Hao S; Hu W; Liu C; Zhang W; Deng X; Chen L; Ma L; Tao R
    Cell Physiol Biochem; 2017; 43(1):353-366. PubMed ID: 28869950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Umbilical cord blood-derived mesenchymal stem cells ameliorate graft-versus-host disease following allogeneic hematopoietic stem cell transplantation through multiple immunoregulations.
    Wu QL; Liu XY; Nie DM; Zhu XX; Fang J; You Y; Zhong ZD; Xia LH; Hong M
    J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):477-484. PubMed ID: 26223913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.